ArticleInternational journal of endocrinology2023
Expression and Clinical Significance of Plasma miR-223 in Patients with Diabetic Nephropathy.
Article in International journal of endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- Common miRNAs, Genes, and Regulatory Pathways in Alzheimer's Disease and Type 2 Diabetes Mellitus: An Integrative Analysis of Systematic Reviews, Bioinformatics and Data Mining.Journal of neurochemistry · 2025Pooled it
- Clinical Utility of Urinary Cystatin C in Early Screening and Staging of Diabetic Kidney Disease in Type 2 Diabetes.International journal of endocrinology · 2026Article
- The Role and Clinical Significance of miR-484 in the Regulation of SGLT2 in Diabetic Nephropathy.International journal of endocrinology · 2026Article
- Exploring the Evidence for Personalized Pharmacotherapy in Type 2 Diabetes-A Systematic Review.Journal of personalized medicine · 2025Review
- Prognostic value of microRNA-495-3p, adiponectin, and cardiometabolic index in type 2 diabetic nephropathy.World journal of diabetes · 2025Article
- Acrolein exposure associated with kidney damage: a cross‑sectional study.Scientific reports · 2025Article
- Characterizing Circulating microRNA Signatures of Type 2 Diabetes Subtypes.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: MicroRNA-223 (miR-223) is associated with diabetes and kidney diseases and serves as a novel marker for diagnosing diabetic kidney disease (DKD). This study was conducted to investigate the plasma expression of miR-223 and its clinical significance in type 2 diabetes (T2DM) and diabetic nephropathy (DN) patients. Methods: In this research, 20 patients with T2DM and DN, 19 patients with T2DM, and 17 healthy volunteers were finally enrolled. miR-223 expression was detected by quantitative real-time PCR (qPCR), and the diagnostic value of miR-223 in DN was further analyzed. Results: miR-223 was downregulated in the DN group compared to that in the T2DM group ( Conclusion: miR-223 was lowly expressed in DN patients, and the evaluation of miR-223 may be a good approach for diagnosing DN.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.